Chia-Huey Ooi

Publications11
h-index7
Citations499
Highly Influential Citations21
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • M. De Palma
  • 75 Publications, 8,786 Citations
  • C. Ries
  • 61 Publications, 2,894 Citations
  • D. Rüttinger
  • 41 Publications, 1,515 Citations
  • R. Vonderheide
  • 256 Publications, 16,346 Citations
  • Publications
  • Influence
Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade
Combination of antiangiogenic treatment and immune checkpoint inhibition improves antitumor immunity. Antitumor attack on two fronts The use of immune checkpoint inhibitors and other immunotherapies… Expand
  • 196
  • 8
  • PDF
Suppression of microRNA activity amplifies IFN-γ-induced macrophage activation and promotes anti-tumour immunity
Tumour-associated macrophages (TAMs) largely express an alternatively activated (or M2) phenotype, which entails immunosuppressive and tumour-promoting capabilities. Reprogramming TAMs towards a… Expand
  • 121
  • 5
Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity
Depletion of immunosuppressive tumor-associated macrophages (TAMs) or reprogramming toward a proinflammatory activation state represent different strategies to therapeutically target this abundant… Expand
  • 71
  • 3
Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
Blockade of colony-stimulating factor-1 receptor (CSF-1R) enables the therapeutic targeting of tumor-associated macrophages (TAM) in cancer patients. Various CSF-1R inhibitors, mAbs, and tyrosine… Expand
  • 25
  • 3
Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response
Recent studies have revealed a role for macrophages and neutrophils in limiting chemotherapy efficacy; however, the mechanisms underlying the therapeutic benefit of myeloid-targeting agents in… Expand
  • 33
  • 1
Tissue-Specific Immunoregulation: A Call for Better Understanding of the "Immunostat" in the Context of Cancer.
Checkpoint inhibitor therapy has been a breakthrough in cancer research, but only some patients with cancer derive substantial benefit. Although mechanisms underlying sensitivity and resistance to… Expand
  • 25
  • 1
Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [18F] FDG-PET imaging combined with proteomic approaches
BackgroundInhibition of mitogen-activated protein kinase (MEK, also known as MAPK2, MAPKK), a key molecule of the Ras/MAPK (mitogen-activated protein kinase) pathway, has shown promising effects on… Expand
  • 8
  • PDF
The gene signature in CCAAT-enhancer-binding protein α dysfunctional acute myeloid leukemia predicts responsiveness to histone deacetylase inhibitors
C/EPBα proteins, encoded by the CCAAT-enhancer-binding protein α gene, play a crucial role in granulocytic development, and defects in this transcription factor have been reported in acute myeloid… Expand
  • 11
  • PDF
Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy
Significance Cancer immunotherapy demonstrates clinical efficacy in selected cancer types. Yet, as the majority of patients do not respond to the most effective immunotherapeutics, novel… Expand
  • 9
Analysis of Spatial Organization of Suppressive Myeloid Cells and Effector T Cells in Colorectal Cancer—A Potential Tool for Discovering Prognostic Biomarkers in Clinical Research
The development and progression of solid tumors such as colorectal cancer (CRC) are known to be affected by the immune system and cell types such as T cells, natural killer (NK) cells, and natural… Expand